Home›Companies›Biotech & Pharma›IconOVir Bio

IconOVir Bio, Inc.

Updated Oct 27, 2026·Latest SEC filing Jun 4, 2024·Suggest an edit

About IconOVir Bio

IconOVir Bio is a private company based in New York, New York. It has reported $97,228,631 raised in two offerings on Form D since December 2020.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jun 6, 2023Jun 21, 2023amended Jun 4, 2024$20,230,000fully sold34$595KDebt, Securities on exerciseRule 506(b)Form D/A ↗1 earlier filing
Dec 1, 2020Dec 14, 2020$76,998,631fully sold47$1.6MEquityRule 506(b)Form D ↗
Total, two offerings$97,228,631

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on IconOVir Bio's Form D filed Jun 4, 2024.

SA
Sean Algeo
Executive officer and promoter
NL
Nicole van de Leuv
Executive officer
HK
Helen Kim
Director
Also a director at Aktis Oncology and Recode Therapeutics.
HN
Heba Nowyhed
Executive officer
DC
David Chang
Director and promoter
WK
JL
Jakob Loven
Director
JK
Joshua Kazam
Director and promoter
JM
Julie Maltzman
Executive officer
MM
Mark McCamish
Executive officer and director
JH
John Huynh
Executive officer
DT
David Tanen
Secretary

Earlier filings also listed Arie Belldegrun (director and promoter, last listed Dec 2020).

Sources

  1. SECIconOVir Bio, Inc. Form D, filed Jun 21, 2023
  2. SECIconOVir Bio, Inc. filing history